Patients
-
News
Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
Read More » -
News
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
Read More » -
News
The ”International Blood Diseases Symposium” Is Just Around The Corner
The Turkish Federation of Blood Diseases, Kan Hastalıkları Federasyonu is joining forces with TIF for the organisation of the ”International Blood Diseases Virtual Symposium”, which will be held virtually on…
Read More » -
News
TIF Has Joined the EASL Patient Organisations Community
TIF is constantly fortifying synergies with influential patient organisations for the benefit of individuals with thalassaemia and other Haemoglobin Disorders. Therefore, we are excited to announce that the Federation has recently joined one…
Read More » -
News
Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial
One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical…
Read More » -
Member News
Malaysian Health Minister: The Country Needs More Geneticists to Detect Thalassaemia Early
Malaysia needs more geneticists in order to identify thalassaemia patients at an early stage, stated Health Minister Datuk Seri Dr Adham Baba, after launching the 2019 Malaysia Thalassaemia Registry (MTR)…
Read More » -
Clinical News
Coronavirus Pandemic: How Close Are We to a Vaccine?
Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO). Vaccines normally require years of testing…
Read More » -
News
TIF Publishes its Annual Report for 2019
This Annual Report showcases the Federation’s intensive efforts that took place in 2019 with the aim to ensure equal access to quality healthcare for every patient with thalassaemia and haemoglobin…
Read More » -
News
Viral Hepatitis & Thalassaemia: Q&A with Prof. John Koskinas
On the occasion of today´s World Hepatitis Day and with the aim of informing and raising awareness among patients with thalassaemia – and not only – about viral hepatitis that…
Read More » -
News
Novartis sickle cell drug Adakveo put on path to EU approval
Novartis announced last Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of Adakveo® (crizanlizumab)…
Read More »